Search Results - "Losenkov, I.S."

P.2.a.008 Correlation between levels of Akt1/GSK-3β signaling pathway proteins and severity of depressive symptoms by Bokhan, N.A, Losenkov, I.S, Vyalova, N.M, Simutkin, G.G, Ivanova, S.A

Get full text

P.0579 Pharmacogenetic study to elucidate putative dopaminergic mechanisms of antidepressant action by Ochi, T., Vyalova, N.M., Losenkov, I.S., Paderina, D.Z., Pozhidaev, I.V., Loonen, A.J.M., Simutkin, G.G., Bokhan, N.A., Wilffert, B., Ivanova, S.A.

Get full text

P.1.a.006 - Association of dopamine transporter gene SLC6A3 polymorphisms with remission and antidepressant therapy response in patients with depressive disorders by Losenkov, I.S., Pozhidaev, I.V., Osmanova, D.Z., Simutkin, G.G.

Get full text

Association of dopamine transporter gene SLC6A3 polymorphisms with remission and antidepressant therapy response in patients with depressive disorders by Losenkov, I.S., Pozhidaev, I.V., Osmanova, D.Z., Simutkin, G.G.

Get full text

Gene polymorphisms of enzymes biotransformation of xenobiotics in patients with depressive disorders by Levchuk, L., Losenkov, I.S., Lebedeva, E.V., Schastnyy, E.D., Perchatkina, O.E., Bokhan, N.A.

Get full text

P.2.b.029 - Gene polymorphisms of enzymes biotransformation of xenobiotics in patients with depressive disorders by Levchuk, L., Losenkov, I.S., Lebedeva, E.V., Schastnyy, E.D., Perchatkina, O.E., Bokhan, N.A.

Get full text

Biomarkers of depressive disorders: A multiplex analysis of blood serum by Boiko, A.S., Losenkov, I.S., Levchuk, L.A., Simutkin, G.G., Bokhan, N.A., Bosker, F.J., Wilffert, B., Loonen, A.J.M., Ivanova, S.A.

“…Depressive disorders are a great burden for individual patients and society. Blood-based biomarkers are regarded as a feasible option for investigation of…”
Get full text

Lithium in the psychopharmacology of affective disorders and mechanisms of its effects on cellular physiology by Losenkov, I S, Plotnikov, E V, Epimakhova, E V, Bokhan, N A

“…However, despite successful use of lithium in the treatment of affective disorders for almost 40 years, the mechanisms of its therapeutic action are still…”
Get more information